President Donald Trump speaks speaks on the latest developments of the coronavirus outbreak, while flanked by White House coronavirus response coordinator Debbie Birx (L), and U.S. Surgeon General Jerome Adams (R), in the James Brady Press Briefing Room at the White House March 19, 2020. (Photo by Chip Somodevilla/Getty Images)
President Donald Trump in a press conference on Thursday said the Food and Drug Administration is fast-tracking efforts to approve an antiviral therapy, best known for treating malaria, for use in coronavirus cases.
The drug, hydroxychloroquine, was developed more than a half-century ago and is approved for treating malaria, arthritis, and other ailments. Reports out of China and Italy suggest the drug may help, but there is no hard data yet.
"We're going to be able to make that drug available almost immediately," Trump said.
The FDA is working to conduct a "large, pragmatic clinical trial" quickly to confirm the drug's benefit to coronavirus patients, said Commissioner Dr. Stephen Hahn.
He also tempered the president's optimism about the still-untested solution.
"What's also important is not to provide false hope," he said. "We may have the right drug, but it might not be in the appropriate dosage form right now, and it might do more harm than good."
New antiviral therapies face a shorter and less arduous approval process than vaccines, several of which are under development with 12 to 18-month timelines.
"The therapies are something we could move on much faster potentially," Trump said.
He claimed the administration "slashed red tape" to develop new vaccines and therapies.
The president also held out on confirming whether he would invoke the Defense Production Act, which he signed on Wednesday, to mandate the production of needed medical supplies such as N95 respirators and surgical masks.
"If we find that we need something, then we will do that," he said.
Trump repeated that he was open to the federal government buying equity stakes in the airline, cruise, hospitality, and other industries hurt by the outbreak.
The press conference opened with more controversial language placing the blame squarely on China for the outbreak, despite concerns voiced about potentially exacerbating a backlash against Asian Americans.
"We continue our relentless effort to defeat the Chinese virus," Trump said.
Democrats are hoping to pass the Build Back Better Infrastructure Bill this week, but fellow Democrat Senator Joe Manchin has proven to be a steady fast hold out, stating that he will not support a multi-trillion dollar bill without greater clarity. U.S. News and World Reports Political Reporter Lisa Hagen joined Cheddar to discuss the future of the bill.
Carlo and Baker discuss the election results across the country, including a Republican comeback in Virginia -- and possibly NJ -- plus the CDC gives the go-ahead for child vaccinations, Atlanta wins the World Series and more.
David Wagner, Portfolio Manager at Aptus Capital Advisors, joins Cheddar News' Closing Bell, where he explains why we continue to see record closes from the Dow, S&P, and Nasdaq, and breaks down figures from Lyft's Q3 earnings report.
Voters across the country are heading to the polls today for Election Day. The results of some key races could signal what we can expect in upcoming elections. In Virginia, Democrat Terry McAuliffe is facing off against Republican Glenn Youngkin for governor in a tight race. The race has both parties watching because it's a big indicator of how voters are leaning ahead of the 2022 midterm elections. Kyle Kondik, managing editor of Sabato's Crystal Ball at the University of Virginia Center for Politics, joins Cheddar News to talk about what's in store for the state.
Laura Vozzella, local reporter for The Washington Post, joins Cheddar News to discuss the close gubernatorial race in Virginia and what voters are looking for in each candidate.
The U.S. Supreme Court takes a closer look at the Texas abortion law that was designed by its sponsors to evade constitutional review in federal court. Katie Barlow, journalist and social media editor at SCOTUSblog joins Cheddar News to breakdown what was discussed.
John Paul Mejia, the national spokesperson for the Sunrise Movement, joined Cheddar to talk about what the youth activist group wants to see from President Joe Biden as he attends the COP26 climate summit. Mejia admonished the president for having little to deliver on his own climate agenda domestically while at the conference. "We need the president to follow through with his promises because, frankly, it's a matter of life or death not only for communities here in the United States but also those looking to us around the world," he said.
With COP26 kicking off, roughly 120 world leaders and delegates are in Glasgow, Scotland to hold climate talks this week. As experts continue to warn about the dangers of climate change, ESG investing is more important than ever.
Georges Archibald, Head of Apex Americas at Apex Group joined Cheddar's Opening Bell to discuss.
President Biden expected to unveil details on a Covid-19 vaccine mandate for businesses in coming days.
This comes just days after The White House issued separate vaccine mandates for federal contractors across the country. Mark Kluger, Founding Partner, employment law firm Kluger Healey joined Cheddar's Opening Bell to discuss.
